Physician profile
Anamika Katoch
NPI 1194938324
$225,425.74
in general payments reported to CMS, 2019-2025
42 companies · $26K in 2025
The $26K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71K · 2020: $20K · 2021: $32K · 2022: $33K · 2023: $31K · 2024: $13K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Travel and Lodging: $12K · Food and Beverage: $4,758 · Consulting Fee: $2,625 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,375.00 |
| Travel and Lodging | $11,613.98 |
| Food and Beverage | $4,757.66 |
| Consulting Fee | $2,625.00 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $205,816.78 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Kite Pharma, INC. | $5,414.95 | 2019-2020 | |
| Avyxa Pharma, LLC | $3,869.23 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $3,004.94 | 2022-2025 | Imfinzi, Lynparza, Truqap |
| E.R. Squibb & Sons, L.L.C. | $1,837.21 | 2020-2025 | Opdivo |
| Puma Biotechnology, INC. | $1,125.00 | 2019 | |
| Daiichi Sankyo INC. | $677.49 | 2022-2025 | Enhertu |
| Emd Serono, INC. | $500.00 | 2021 | |
| Genzyme Corporation | $478.65 | 2019-2023 | |
| Incyte Corporation | $250.00 | 2022 | |
| Seagen INC. | $249.99 | 2019-2023 | Tukysa |
| Pfizer INC. | $196.81 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $195.63 | 2022-2023 | Keytruda, Lynparza, Welireg |
| Beigene USA, INC. | $181.13 | 2023-2025 | Brukinsa, Tevimbra |
| Beone Medicines USA, INC. | $172.62 | 2025 | Brukinsa |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $145.72 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Pharmaessentia USA Corporation | $125.00 | 2025 | Besremi |
| Eisai INC. | $124.39 | 2024 | |
| Sobi, INC | $102.56 | 2023-2024 | |
| Caris Mpi, INC. | $101.95 | 2025 | Mi Cancer Seek |
| Sanofi-Aventis U.S. LLC | $99.95 | 2019 | |
| Janssen Biotech, INC. | $97.20 | 2019-2025 | Erleada, Carvykti |
| Novartis Pharmaceuticals Corporation | $66.15 | 2023-2024 | |
| Genentech USA, INC. | $65.53 | 2019-2023 | Venclexta |
| Tempus Ai, INC | $50.23 | 2025 | Xt Cdx |
| Adaptive Biotechnologies Corporation | $45.65 | 2025 | Clonoseq |
| Celgene Corporation | $40.84 | 2023-2024 | Reblozyl |
| Array Biopharma INC | $39.95 | 2025 | Braftovi, Mektovi, Tukysa |
| Abbvie INC. | $38.35 | 2023-2025 | |
| Genmab U.S., INC. | $34.32 | 2023 | Tivdak |
| Gilead Sciences, INC. | $32.16 | 2021-2023 | |
| Stemline Therapeutics INC. | $28.14 | 2023 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $27.68 | 2023 | Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $27.21 | 2025 | Iclusig |
| Bayer Healthcare Pharmaceuticals INC. | $25.72 | 2024 | |
| Jazz Pharmaceuticals INC. | $23.19 | 2023 | |
| Acrotech Biopharma INC. | $22.18 | 2023 | Beleodaq |
| Regeneron Healthcare Solutions, INC. | $20.06 | 2024 | Libtayo |
| Blueprint Medicines Corporation | $19.92 | 2023 | Ayvakit |
| Astellas Pharma US INC | $19.65 | 2025 | Vyloy |
| Servier Pharmaceuticals LLC | $18.38 | 2023 | |
| Amgen INC. | $13.23 | 2023 | Kyprolis, Blincyto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anamika Katoch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.